Advertisement

Annals of Surgical Oncology

, Volume 15, Issue 1, pp 69–79 | Cite as

Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients

  • Eva Lieto
  • Francesca Ferraraccio
  • Michele Orditura
  • Paolo Castellano
  • Anna La Mura
  • Margherita Pinto
  • Anna Zamboli
  • Ferdinando De Vita
  • Gennaro Galizia
Gastrointestinal Oncology Original Papers

Abstract

Background

Unlike other human tumors, gastric cancer remains a great therapeutic challenge since no standardized postoperative treatment exists. Knowledge of molecular pathways determining the behavior of individual gastric tumors seems to be crucial for therapeutic decisions, and evaluation of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expression might be critical for prognosis, assessment, and identification of patients that could be treated with tailored therapies.

Methods

VEGF and EGFR determination was performed in 88 gastric cancer samples as well as 25 normal gastric mucosa specimens from non-cancer patients using a commercially available immunohistochemistry kit. In all samples, the correlation of VEGF and EGFR expression was investigated with each other, and with other prognostic indicators in all samples, and, finally, with survival rates in 69 patients undergoing potentially curative surgery.

Results

Forty-eight per cent (42 cases) of gastric cancers expressed VEGF, and 44% (39 cases) stained for EGFR. In curatively treated patients, VEGF and EGFR expression was demonstrated to correlate with worse survival in both univariate and multivariate analyses. Molecular profiling was shown to more accurately estimate the risk of cancer-related death than TNM stage, and, of most interest, to allow sorting out high-risk patients within the same stage.

Conclusions

These findings provide evidence that contemporary evaluation of VEGF and EGFR expression may be crucial to select gastric cancer patients with poor prognosis who may benefit of tailored treatments.

Keywords

Gastric cancer Prognostic factors Vascular endothelial growth factor Epidermal growth factor receptor Targeted biological therapy 

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics. CA Cancer J Clin 2006; 56:106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107PubMedCrossRefGoogle Scholar
  3. 3.
    Hartgrink HH, van de Velde CJ. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005; 90:153–165PubMedCrossRefGoogle Scholar
  4. 4.
    Novotny AR, Schuhmacher C, Bush R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a US-derived nomogram at a single high-volume center in Europe. Ann Surg 2006; 243:74–81PubMedCrossRefGoogle Scholar
  5. 5.
    Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23:1237–1244PubMedCrossRefGoogle Scholar
  6. 6.
    Allal AS, Zwahlen D, Brundler MA, de Peyer R, Morel P, Huber O, Roth AD. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2005; 63:1286–1289PubMedCrossRefGoogle Scholar
  7. 7.
    Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63:1279–1285PubMedCrossRefGoogle Scholar
  8. 8.
    MacDonald JS. Gastric cancer – new therapeutic options. N Engl J Med 2006; 355:76–77PubMedCrossRefGoogle Scholar
  9. 9.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20PubMedCrossRefGoogle Scholar
  10. 10.
    Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized duthc gastric cancer group trial. J Clin Oncol 2004; 22:2069–2077PubMedCrossRefGoogle Scholar
  11. 11.
    Hundahl SA, Wanebo HJ. Changing gastric cancer treatment in the United States and the pursuit of quality. Eur J Surg Oncol 2005; 31:605–615PubMedCrossRefGoogle Scholar
  12. 12.
    Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and a meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903–2909PubMedCrossRefGoogle Scholar
  13. 13.
    Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005; 31:453–460PubMedCrossRefGoogle Scholar
  14. 14.
    Sutter AP, Zeitz M, Scherübl H. Recent results in understanding molecular patways in the medical treatment of esophageal and gastric cancer. Onkologie 2004; 27:17–21PubMedCrossRefGoogle Scholar
  15. 15.
    Jüttner S, Wißmann C, Jöns T, et al. Vascular endothelial growth factor-D and ist receptor VEGF-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24:228–239PubMedCrossRefGoogle Scholar
  16. 16.
    Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13:1794–1798PubMedGoogle Scholar
  17. 17.
    Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:2445–2459PubMedCrossRefGoogle Scholar
  18. 18.
    Tzanakis N, Gazouli M, Rallis G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 2006; 94:624–630PubMedCrossRefGoogle Scholar
  19. 19.
    Ding S, Li C, Lin S, et al. Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep 2007; 17:369–375PubMedGoogle Scholar
  20. 20.
    Saito H, Osaki T, Murakami D, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123–128PubMedCrossRefGoogle Scholar
  21. 21.
    Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 2007; 30:633–637PubMedCrossRefGoogle Scholar
  22. 22.
    Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007; 31:1458–1468PubMedCrossRefGoogle Scholar
  23. 23.
    Boku N, Ohtsu A, Yoshida S, et al. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007; 37:275–281PubMedCrossRefGoogle Scholar
  24. 24.
    Fondevila C, Metges JP, Fuster JJ, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90:206–215PubMedCrossRefGoogle Scholar
  25. 25.
    Lang SA, Klein D, Moser C, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007; 6:1123–1132PubMedCrossRefGoogle Scholar
  26. 26.
    Ito R, Nakayama H, Yoshida K, Matsumura S, Oda N, Yasui W. Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch 2004; 444:324–331PubMedCrossRefGoogle Scholar
  27. 27.
    Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787–2799PubMedCrossRefGoogle Scholar
  28. 28.
    Romano M, Ricci V, Zarrilli R. Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis–implications for chemoprevention. Nat Clin Pract Gastroenterol Hepatol 2006; 3:622–632PubMedCrossRefGoogle Scholar
  29. 29.
    Grogg KL, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003; 16:641–651PubMedCrossRefGoogle Scholar
  30. 30.
    Hiyama T, Tanaka S, Yoshihara M, et al. Chromosomal and microsatellite instability in sporadic gastric cancer. J Gastroenterol Hepatol 2004; 19:756–760PubMedCrossRefGoogle Scholar
  31. 31.
    AJCC Cancer staging manual. 6th Edition. Ed. Springer-Verlag., pp.99–106, 2002Google Scholar
  32. 32.
    Galizia G, Lieto E, Ferrarraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004; 10:3490–3499PubMedCrossRefGoogle Scholar
  33. 33.
    Galizia G, Lieto E, Ferrarraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13:823–835PubMedCrossRefGoogle Scholar
  34. 34.
    Chan YH. Biostatistics 203. Survival analysis. Singapore Med J 2004; 45:249–256PubMedGoogle Scholar
  35. 35.
    Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–939PubMedCrossRefGoogle Scholar
  36. 36.
    Bonavida B. Preface: antibody therapy for cancer. Oncogene 2007; 26:3592–3593PubMedCrossRefGoogle Scholar
  37. 37.
    McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004; 3:1041–1048PubMedGoogle Scholar
  38. 38.
    Ciardiello F, Troiani T, Bianco R, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006; 17(suppl_7):vii109–vii114PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Eva Lieto
    • 1
  • Francesca Ferraraccio
    • 2
  • Michele Orditura
    • 3
  • Paolo Castellano
    • 1
  • Anna La Mura
    • 2
  • Margherita Pinto
    • 1
  • Anna Zamboli
    • 1
  • Ferdinando De Vita
    • 3
  • Gennaro Galizia
    • 1
  1. 1.Divisions of Surgical Oncology, F. Magrassi - A. Lanzara Department of Clinical and Experimental Medicine and SurgerySecond University of Naples School of MedicineNaplesItaly
  2. 2.Divisions of Pathology, F. Magrassi - A. Lanzara Department of Clinical and Experimental Medicine and SurgerySecond University of Naples School of MedicineNaplesItaly
  3. 3.Divisions of Medical Oncology, F. Magrassi - A. Lanzara Department of Clinical and Experimental Medicine and SurgerySecond University of Naples School of MedicineNaplesItaly

Personalised recommendations